Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Baseline expression of symptomatic and asymptomatic subjects after YF17D vaccination in Trial 1

ABSTRACT: This study investigates how the baseline expression level of genes impact symptomatic outcome of flaviviral infection. Before given the YF17D vaccine, whole blood was extracted into tempus tubes from vaccinated subjects. Thereafter, the subjects were assessed if they experienced adverse events (or symptoms). 27 subjects (n=19 symptomatic, n=8 asymptomatic) were processed according to manufacturer's protocol. Transcript expression was then evaluated by Affymetrix Human GeneChip 2.0 ST array, performed at Duke-NUS Genome Biology Core Facility. Data analysis and processing was performed using Partek software and enriched pathways determined by Reactome database from Enrichr.

ORGANISM(S): Homo sapiens

SUBMITTER: Kuan Rong Chan

PROVIDER: E-MTAB-7928 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

Baseline expression of symptomatic and asymptomatic subjects after YF17D vaccination in Trial 2

Project description:This study investigates how the baseline expression level of genes impact symptomatic outcome of flaviviral infection. Before given the YF17D vaccine, whole blood was extracted into tempus tubes from vaccinated subjects. Thereafter, the subjects were assessed if they experienced adverse events (or symptoms). 35 subjects (n=12 symptomatic, n=23 asymptomatic) were processed according to manufacturer's protocol. Transcript expression was then evaluated by nCounter RNA Cancer Metabolism (#VRXC-CM1-12) or a custom Unfolded Protein Response codeset and its respective probesets.

2019-05-11 | E-MTAB-7931 | biostudies-arrayexpress

RNA-seq of healthy individuals that received placebo or gentamicin prior to YF17D vaccination

Project description:RNA was extracted from whole blood of subjects collected in Tempus tubes. We assessed host response over time following YF17D vaccination in placebo and gentamicin groups.

2026-05-15 | E-MTAB-16858 | biostudies-arrayexpress

RNA-seq of peripheral whole blood samples comparing obese and non-obese individuals upon inoculation with yellow fever virus vaccine (YF17D)

Project description:RNA was extracted from whole blood samples in Tempus tubes at baseline, day 1 (D1), D4, D6, and D28 after YF17D inoculation. We investigated differences in gene expression between obese (25<BMI<=35) and non-obese individuals (18<=BMI<=25) throughout the different timepoints.

2026-03-14 | E-MTAB-16701 | biostudies-arrayexpress

Early gene expression after YF17D vaccination that is associated with YF17D-specific T cell responses

Project description:Early gene expression after YF17D vaccination that is associated with YF17D-specific T cell responses

| PRJEB90158 | ENA

Early gene expression after YF17D vaccination that is associated with YF17D-specific T cell responses

Project description:This study investigates the post-vaccination gene expression associated with T cell response and why humoral immunity does not inform cellular responses post-vaccination. The experiment is the transcriptional profiling of peripheral blood mononuclear cells (PBMCs) from 12 subjects collected at day 0, day 4, day 7 and day 10 post yellow fever (YF) vaccination.

2026-04-14 | E-MTAB-15199 | biostudies-arrayexpress

Whole Blood Transcriptional Profiling Differentiates Between Asymptomatic and Symptomatic Human Rhinovirus Detection in Children

Project description:Human rhinoviruses (HRV) are among the most common causes of respiratory infections in humans but can be frequently detected also in asymptomatic subjects. We evaluated the value of gene expression profiles to differentiate asymptomatic detection from symptomatic HRV infection in children.

2016-01-14 | GSE67059 | GEO

Evaluation of a chimeric YF-ZIK vaccine candidate in rhesus macaques

Project description:In this study, we designed and assessed the immunogenicity and protective efficacy of a chimeric live-attenuated vaccine derived from the yellow fever 17D (YF17D) backbone engineered to express ZIKV antigens. We immunized rhesus macaques with two subcutaneous doses, which rapidly induced neutralizing antibodies and balanced Th1/Th2 responses similar to YF17D. Passive serum transfer protected AG129 mice, confirming antibodies as a key correlate of protection. Upon high-dose ZIKV challenge, vaccinated macaques showed no detectable viral RNA or NS1 seroconversion, indicating sterilizing immunity. Systems analyses revealed TNFRSF17, GNAS, and CD207 as biomarkers linked to antibody responses and immune outcomes. Overall, our workflow demonstrates that YF-ZIK is safe, strongly immunogenic, and protective, supporting its progression to human trials.

2025-10-28 | E-MTAB-15887 | biostudies-arrayexpress

Cross-reactive antibodies enhance live attenuated virus infection for increased immunogenicity

Project description:Transcriptional profiling of peripheral blood mononuclear cells (PBMCs) from 30 subjects collected at day 0, day 1 and day 3 post yellow fever (YF) vaccination. Each patient sample is performed in duplicate to reduce the chance of error. Briefly, the project investigates how cross-reactive JE antibodies that are generated from prior vaccination can influence YF live-attenuated vaccine (LAV). The groups are hence segregated based on the YF antibody titers after 1 month vaccination. Group 4 refers to the control group where individuals received only the YF LAV. Enhancing group refers to the treatment group (given JE followed by YF vaccine), where individuals had YF antibody titers higher than 99% confidence interval of the YF antibody titers of the control group. Non-enhancing group, on the other hand, refers to the treatment group where individuals had YF antibody titers within or lower 99% confidence interval of the control group. Our present study provides evidence that enhancing levels of cross-reactive antibodies from prior Japanese encephalitis (JE) vaccination can improve subsequent YF immunogenicity. These microarray results indicate the genes and gene signatures that are associated with the differences in YF immunogenicity.

2017-09-05 | E-MTAB-4669 | biostudies-arrayexpress

Blood genome expression Profiles in Infants with Congenital Cytomegalovirus Infection: Is the asymptomatic infant truly asymptomatic?

Project description:Background: Congenital cytomegalovirus (cCMV) infection represents the most frequent non-genetic cause of sensorineural hearing loss (SNHL). The disease spectrum varies from clinically apparent (“symptomatic”) to clinically inapparent (“asymptomatic”). Analysis of host genome expression profiles has provided new insights into disease pathogenesis and assessment of clinical severity. Its value as a biomarker in infants with cCMV has not been explored. Methods: Infants with cCMV infection, both symptomatic and asymptomatic, were enrolled at a median age of 17 days of age and followed up for 3 years to assess the development of SNHL. Healthy age matched controls were also enrolled as a reference. Blood samples were obtained at enrollment and follow-up to assess host responses by RNA transcriptional profiling. Symptomatic CMV was defined as the presence of any clinical, laboratory, ophthalmologic, audiologic or neuroimaging abnormalities.

2020-05-26 | GSE108211 | GEO

Transcriptomic profiling facilitates classification of response to influenza challenge

Project description:Despite increases in vaccination coverage, reductions in influenza-related mortality have not been observed. Better vaccines are therefore required and influenza challenge studies can be used to test the efficacy of new vaccines. However, this requires the accurate post-challenge classification of subjects by outcome, which is limited in current methods that use artificial thresholds to assign “symptomatic” and “asymptomatic” phenotypes. We present data from an influenza challenge study in which 22 healthy adults (11 vaccinated) were inoculated with H3N2 influenza (A/Wisconsin/67/2005). We generated genome-wide gene expression data from peripheral blood taken immediately before the challenge and at 12, 24, and 48 hours post-challenge. Variation in symptomatic scoring was found among those with laboratory confirmed influenza. By combining the dynamic transcriptomic data with the clinical parameters this variability can be reduced. We identified four subjects with severe laboratory confirmed flu that show differential gene expression in 1,103 probes 48 hours post-challenge compared to the remaining subjects. We have further reduced this profile to 6 genes that can be used to define these subjects. We have used this gene set to predict symptomatic infection from an independent study. This analysis gives further insight into host-pathogen interactions during influenza infection. However, the major potential value is in the clinical trial setting by providing a more quantitative method to better classify symptomatic individuals post influenza challenge. Twenty two healthy volunteers were enrolled for an influenza challenge study. Eleven were vaccinated thirty days before challenge with H3N2 influenza. Whole blood was collected in PAXgene tubes prior to influenza challenge and then at three further timepoints (12, 24 and 48 hours post-challenge).

2014-11-06 | E-GEOD-61754 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data